186 related articles for article (PubMed ID: 20054688)
1. Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.
Matsushita N; Komine H; Grolleau-Julius A; Pilon-Thomas S; Mulé JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):875-84. PubMed ID: 20054688
[TBL] [Abstract][Full Text] [Related]
2. Examination of MARCO activity on dendritic cell phenotype and function using a gene knockout mouse.
Komine H; Kuhn L; Matsushita N; Mulé JJ; Pilon-Thomas S
PLoS One; 2013; 8(7):e67795. PubMed ID: 23840879
[TBL] [Abstract][Full Text] [Related]
3. Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays.
Grolleau A; Misek DE; Kuick R; Hanash S; Mulé JJ
J Immunol; 2003 Sep; 171(6):2879-88. PubMed ID: 12960310
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
6. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
7. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
8. The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy.
Woo SC; Kim GY; Lee CM; Moon DO; Kim HK; Lee TH; Moon YS; Park NC; Yoon MS; Lee KS; Park YM
Cancer Biol Ther; 2005 Dec; 4(12):1331-5. PubMed ID: 16322691
[TBL] [Abstract][Full Text] [Related]
9. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
[TBL] [Abstract][Full Text] [Related]
10. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
11. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.
Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M
Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
16. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
18. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
19. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
20. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
Tan C; Reddy V; Dannull J; Ding E; Nair SK; Tyler DS; Pruitt SK; Lee WT
J Transl Med; 2013 Jun; 11():148. PubMed ID: 23768240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]